Adaptive Biotechnologies (ADPT) reported $52.44 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 25.3%. EPS of -$0.20 for the same period compares to -$0.33 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $43.15 million, representing a surprise of +21.53%. The company delivered an EPS surprise of +28.57%, with the consensus EPS estimate being -$0.28.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Adaptive Biotechnologies performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- ClonoSEQ test volume: 23,117 versus the three-analyst average estimate of 23,468.
- Revenues- Total MRD: $43.72 million versus the three-analyst average estimate of $34.61 million. The reported number represents a year-over-year change of +34%.
- Revenues- Total Immune Medicine: $8.72 million versus $8.50 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -5.7% change.
View all Key Company Metrics for Adaptive Biotechnologies here>>>
Shares of Adaptive Biotechnologies have returned -7.3% over the past month versus the Zacks S&P 500 composite's -0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Adaptive Biotechnologies Corporation (ADPT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
